{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:50:15Z","timestamp":1793155815677,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100013098","name":"Scientific and Innovative Action Plan of Shanghai","doi-asserted-by":"publisher","award":["16ZR1426600"],"award-info":[{"award-number":["16ZR1426600"]}],"id":[{"id":"10.13039\/501100013098","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Previous studied revealed that psoriasis and Inflammatory bowel disease (IBD) have highly overlapping epidemiological characteristics, genetic susceptibility loci, disease risk factors, immune mechanisms, and comorbidities. More and more biologics have been used to treat psoriasis and IBD. Interleukin (IL)-17 inhibitors played an important role in the treatment of psoriasis, but induced and aggravated inflammatory bowel disease in some patients. IL-23 inhibitors have shown to be effective to both psoriasis and CD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>Forty-one year old Chinese male patient who came to the hospital for psoriasis, developed severe gastrointestinal symptoms after using an IL-17 inhibitor, and was diagnosed with Crohn\u2019s disease (CD). The patient eventually used an IL-23 inhibitor to relieve both psoriasis and CD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>IBD patients and psoriasis patients have increased probability of suffering from the other disease. The case that patients had suffered from psoriasis and CD before the use of IL-17 inhibitor is quite rare. This case suggests that physicians need to be careful when treating patients with psoriasis and CD with biologics, and it is necessary to evaluate the gastrointestinal tract.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-020-01474-x","type":"journal-article","created":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T07:02:59Z","timestamp":1602745379000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Crohn\u2019s disease exacerbated by IL-17 inhibitors in patients with psoriasis: a case report"],"prefix":"10.1186","volume":"20","author":[{"given":"Jingyi","family":"Ju","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaolan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changqin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binghui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiying","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanju","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9307-4735","authenticated-orcid":false,"given":"Xiaomin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,15]]},"reference":[{"key":"1474_CR1","doi-asserted-by":"publisher","first-page":"983902","DOI":"10.1155\/2013\/983902","volume":"2013","author":"N Skroza","year":"2013","unstructured":"Skroza N, Proietti I, Pampena R, La Viola G, Bernardini N, Nicolucci F, Tolino E, Zuber S, Soccodato V, Potenza C. Correlations between psoriasis and inflammatory bowel diseases. Biomed Res Int. 2013;2013:983902.","journal-title":"Biomed Res Int"},{"key":"1474_CR2","first-page":"73","volume":"6","author":"C Vlachos","year":"2016","unstructured":"Vlachos C, Gaitanis G, Katsanos KH, Christodoulou DK, Tsianos E, Bassukas ID. Psoriasis and inflammatory bowel disease: links and risks. Psoriasis. 2016;6:73\u201392.","journal-title":"Psoriasis"},{"issue":"8","key":"1474_CR3","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.crohns.2014.02.002","volume":"8","author":"GC Parkes","year":"2014","unstructured":"Parkes GC, Whelan K, Lindsay JO. Smoking in inflammatory bowel disease: impact on disease course and insights into the aetiology of its effect. J Crohns Colitis. 2014;8(8):717\u201325.","journal-title":"J Crohns Colitis"},{"issue":"1","key":"1474_CR4","first-page":"141","volume":"26","author":"JL Koliani-Pace","year":"2020","unstructured":"Koliani-Pace JL, Haron AM, Zisman-Ilani Y, Thompson KD, Siegel CA. Patients' perceive biologics to be riskier and more dreadful than other IBD medications. Inflamm Bowel Dis. 2020;26(1):141\u20136.","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"1474_CR5","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jaad.2017.06.043","volume":"78","author":"SM Whitlock","year":"2018","unstructured":"Whitlock SM, Enos CW, Armstrong AW, Gottlieb A, Langley RG, Lebwohl M, Merola JF, Ryan C, Siegel MP, Weinberg JM, et al. Management of psoriasis in patients with inflammatory bowel disease: from the medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2018;78(2):383\u201394.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1474_CR6","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jaad.2018.06.039","volume":"80","author":"C Paul","year":"2019","unstructured":"Paul C, Griffiths CEM, van de Kerkhof PCM, Puig L, Dutronc Y, Henneges C, Dossenbach M, Hollister K, Reich K. Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: results from IXORA-S, a phase 3 study. J Am Acad Dermatol. 2019;80(1):70\u201379 e73.","journal-title":"J Am Acad Dermatol"},{"issue":"9993","key":"1474_CR7","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","volume":"386","author":"CEM Griffiths","year":"2015","unstructured":"Griffiths CEM, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541\u201351.","journal-title":"Lancet"},{"issue":"4","key":"1474_CR8","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1056\/NEJMoa1512711","volume":"375","author":"KB Gordon","year":"2016","unstructured":"Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, Reich K, Amato D, Ball SG, Braun DK, et al. Phase 3 trials of Ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345\u201356.","journal-title":"N Engl J Med"},{"key":"1474_CR9","doi-asserted-by":"crossref","unstructured":"Fujino S, Andoh A, Bamba S: Increased expression of interleukin 17 in inflammatory bowel disease. 2003.","DOI":"10.1136\/gut.52.1.65"},{"issue":"1","key":"1474_CR10","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/cei.12086","volume":"173","author":"BJ Lewis","year":"2013","unstructured":"Lewis BJ, Rajpara S, Haggart AM, Wilson HM, Barker RN, Ormerod AD. Predominance of activated, clonally expanded T helper type 17 cells within the CD4+T cell population in psoriatic lesions. Clin Exp Immunol. 2013;173(1):38\u201346.","journal-title":"Clin Exp Immunol"},{"issue":"11","key":"1474_CR11","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/ajg.2016.298","volume":"111","author":"SR Targan","year":"2016","unstructured":"Targan SR, Feagan B, Vermeire S, Panaccione R, Melmed GY, Landers C, Li D, Russell C, Newmark R, Zhang N, et al. A randomized, double-blind, placebo-controlled phase 2 study of Brodalumab in patients with moderate-to-severe Crohn's disease. Am J Gastroenterol. 2016;111(11):1599\u2013607.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"1474_CR12","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/ni.1736","volume":"10","author":"W O'Connor Jr","year":"2009","unstructured":"O'Connor W Jr, Kamanaka M, Booth CJ, Town T, Nakae S, Iwakura Y, Kolls JK, Flavell RA. A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat Immunol. 2009;10(6):603\u20139.","journal-title":"Nat Immunol"},{"issue":"4","key":"1474_CR13","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.immuni.2015.08.019","volume":"43","author":"JR Maxwell","year":"2015","unstructured":"Maxwell JR, Zhang Y, Brown WA, Smith CL, Byrne FR, Fiorino M, Stevens E, Bigler J, Davis JA, Rottman JB, et al. Differential roles for Interleukin-23 and Interleukin-17 in intestinal Immunoregulation. Immunity. 2015;43(4):739\u201350.","journal-title":"Immunity"},{"issue":"12","key":"1474_CR14","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","volume":"61","author":"W Hueber","year":"2012","unstructured":"Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD, Wehkamp J, Feagan BG, Yao MD, Karczewski M, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61(12):1693\u2013700.","journal-title":"Gut"},{"issue":"1","key":"1474_CR15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/09546634.2017.1329511","volume":"29","author":"M Hohenberger","year":"2018","unstructured":"Hohenberger M, Cardwell LA, Oussedik E, Feldman SR. Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease. J Dermatol Treat. 2018;29(1):13\u20138.","journal-title":"J Dermatol Treat"},{"issue":"1","key":"1474_CR16","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12876-019-1067-0","volume":"19","author":"MK Smith","year":"2019","unstructured":"Smith MK, Pai J, Panaccione R, Beck P, Ferraz JG, Jijon H. Crohn's-like disease in a patient exposed to anti-Interleukin-17 blockade (Ixekizumab) for the treatment of chronic plaque psoriasis: a case report. BMC Gastroenterol. 2019;19(1):162.","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"1474_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2174\/1381612825666190313140811","volume":"25","author":"MC Argollo","year":"2019","unstructured":"Argollo MC, Allocca M, Furfaro F, Peyrin-Biroulet L, Danese S. Interleukin-23 blockers: born to be first-line biologic agents in inflammatory bowel disease? Curr Pharm Des. 2019;25(1):25\u201331.","journal-title":"Curr Pharm Des"},{"issue":"3","key":"1474_CR18","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1053\/j.gastro.2010.05.040","volume":"139","author":"T Takayama","year":"2010","unstructured":"Takayama T, Kamada N, Chinen H, Okamoto S, Kitazume MT, Chang J, Matuzaki Y, Suzuki S, Sugita A, Koganei K, et al. Imbalance of NKp44(+)NKp46(\u2212) and NKp44(\u2212)NKp46(+) natural killer cells in the intestinal mucosa of patients with Crohn's disease. Gastroenterology. 2010;139(3):882\u201392 892 e881\u2013883.","journal-title":"Gastroenterology"},{"issue":"1","key":"1474_CR19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.autrev.2016.09.015","volume":"16","author":"LI Sakkas","year":"2017","unstructured":"Sakkas LI, Bogdanos DP. Are psoriasis and psoriatic arthritis the same disease? The IL-23\/IL-17 axis data. Autoimmun Rev. 2017;16(1):10\u20135.","journal-title":"Autoimmun Rev"},{"issue":"3","key":"1474_CR20","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41575-018-0084-8","volume":"16","author":"AR Moschen","year":"2019","unstructured":"Moschen AR, Tilg H, Raine T. IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting. Nat Rev Gastroenterol Hepatol. 2019;16(3):185\u201396.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"1474_CR21","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1177\/2040622316653306","volume":"7","author":"T Engel","year":"2016","unstructured":"Engel T, Kopylov U. Ustekinumab in Crohn's disease: evidence to date and place in therapy. Ther Adv Chron Dis. 2016;7(4):208\u201314.","journal-title":"Ther Adv Chron Dis"},{"issue":"20","key":"1474_CR22","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","volume":"375","author":"BG Feagan","year":"2016","unstructured":"Feagan BG, Sandborn WJ, Gasink C. Ustekinumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2016;375(20):1946\u201360.","journal-title":"N Engl J Med"},{"issue":"2","key":"1474_CR23","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1080\/09546630802441234","volume":"20","author":"JM Ko","year":"2009","unstructured":"Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatol Treat. 2009;20(2):100\u20138.","journal-title":"J Dermatol Treat"},{"issue":"10","key":"1474_CR24","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1111\/jdv.14451","volume":"31","author":"M Amin","year":"2017","unstructured":"Amin M, Darji K, No DJ, Wu JJ. Review of phase III trial data on IL-23 inhibitors tildrakizumab and guselkumab for psoriasis. J Eur Acad Dermatol Venereol. 2017;31(10):1627\u201332.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"1474_CR25","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izz033","volume":"25","author":"LB Grossberg","year":"2019","unstructured":"Grossberg LB. A case report of successful treatment of Crohn's disease and psoriasis with Guselkumab. Inflamm Bowel Dis. 2019;25(7):e84.","journal-title":"Inflamm Bowel Dis"},{"key":"1474_CR26","doi-asserted-by":"publisher","first-page":"101604","DOI":"10.1016\/j.bpg.2019.02.006","volume":"38-39","author":"C Ma","year":"2019","unstructured":"Ma C, Panaccione R, Khanna R, Feagan BG, Jairath V. IL12\/23 or selective IL23 inhibition for the management of moderate-to-severe Crohn's disease? Best Pract Res Clin Gastroenterol. 2019;38-39:101604.","journal-title":"Best Pract Res Clin Gastroenterol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-020-01474-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-020-01474-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-020-01474-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T14:37:48Z","timestamp":1634308668000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-020-01474-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,15]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1474"],"URL":"https:\/\/doi.org\/10.1186\/s12876-020-01474-x","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,15]]},"assertion":[{"value":"6 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval by committee was not required for this case report.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written onsent is available for review by the Editor-in-Chief of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"340"}}